within Pharmacolibrary.Drugs.ATC.S;

model S01BC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01BC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) formerly used for its analgesic and anti-inflammatory properties, primarily in the treatment of rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal conditions. It is a metabolite of phenylbutazone. Due to serious adverse effects including bone marrow suppression and agranulocytosis, oxyphenbutazone has been withdrawn or severely restricted in many countries and is not commonly used today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults assuming typical NSAID PK characteristics. No recent or accessible peer-reviewed publication directly reports detailed PK model for oxyphenbutazone in humans.</p><h4>References</h4><ol><li><p>Aarbakke, J (1978). Clinical pharmacokinetics of phenylbutazone. <i>Clinical pharmacokinetics</i> 3(5) 369–380. DOI:<a href=&quot;https://doi.org/10.2165/00003088-197803050-00003&quot;>10.2165/00003088-197803050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/359213/&quot;>https://pubmed.ncbi.nlm.nih.gov/359213</a></p></li><li><p>Jaraiz, V, et al., &amp; San Andres, MI (1999). Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. <i>Journal of veterinary pharmacology and therapeutics</i> 22(4) 247–254. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2885.1999.00219.x&quot;>10.1046/j.1365-2885.1999.00219.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10499236/&quot;>https://pubmed.ncbi.nlm.nih.gov/10499236</a></p></li><li><p>Verbeeck, RK (1990). Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. <i>Clinical pharmacokinetics</i> 19(1) 44–66. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199019010-00004&quot;>10.2165/00003088-199019010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2199127/&quot;>https://pubmed.ncbi.nlm.nih.gov/2199127</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01BC02;
